Yili Chuanning Biotechnology Co. Ltd. A
Yili Chuanning Biotechnology Co.,Ltd., together with its subsidiaries, engages in the research, development, and industrialization of bio-fermentation technology and synthetic biology products in China and internationally. The company offers antibiotic intermediates comprising erythromycin thiofluorate; cephalosporin intermediates consisting of 7-aminocephalosporanic acid (7-ACA), 7-amino-3-deace… Read more
Yili Chuanning Biotechnology Co. Ltd. A (301301) - Net Assets
Latest net assets as of June 2025: CN¥7.79 Billion CNY
Based on the latest financial reports, Yili Chuanning Biotechnology Co. Ltd. A (301301) has net assets worth CN¥7.79 Billion CNY as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥10.16 Billion) and total liabilities (CN¥2.37 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥7.79 Billion |
| % of Total Assets | 76.65% |
| Annual Growth Rate | 18.33% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 8.08 |
Yili Chuanning Biotechnology Co. Ltd. A - Net Assets Trend (2021–2024)
This chart illustrates how Yili Chuanning Biotechnology Co. Ltd. A's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Yili Chuanning Biotechnology Co. Ltd. A (2021–2024)
The table below shows the annual net assets of Yili Chuanning Biotechnology Co. Ltd. A from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥7.92 Billion | +13.52% |
| 2023-12-31 | CN¥6.97 Billion | +12.28% |
| 2022-12-31 | CN¥6.21 Billion | +30.00% |
| 2021-12-31 | CN¥4.78 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Yili Chuanning Biotechnology Co. Ltd. A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 571.9% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥2.06 Billion | 26.10% |
| Other Components | CN¥5.84 Billion | 73.90% |
| Total Equity | CN¥7.90 Billion | 100.00% |
Yili Chuanning Biotechnology Co. Ltd. A Competitors by Market Cap
The table below lists competitors of Yili Chuanning Biotechnology Co. Ltd. A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Nexwise Intelligence China Limited
SHE:301248
|
$732.07 Million |
|
Energisa S.A
SA:ENGI3
|
$732.17 Million |
|
Tat Techno
NASDAQ:TATT
|
$732.36 Million |
|
SUPERLOOP LTD
F:9SL
|
$732.38 Million |
|
Direcional Engenharia S.A.
SA:DIRR3
|
$731.83 Million |
|
Abcellera Biologics Inc
NASDAQ:ABCL
|
$731.78 Million |
|
Patria Investments Ltd
NASDAQ:PAX
|
$731.78 Million |
|
Shandong Yulong Gold Co Ltd
SHG:601028
|
$730.83 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Yili Chuanning Biotechnology Co. Ltd. A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 6,960,483,793 to 7,897,587,034, a change of 937,103,241 (13.5%).
- Net income of 1,400,324,130 contributed positively to equity growth.
- Dividend payments of 545,072,525 reduced retained earnings.
- Other factors increased equity by 81,851,636.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥1.40 Billion | +17.73% |
| Dividends Paid | CN¥545.07 Million | -6.9% |
| Other Changes | CN¥81.85 Million | +1.04% |
| Total Change | CN¥- | 13.46% |
Book Value vs Market Value Analysis
This analysis compares Yili Chuanning Biotechnology Co. Ltd. A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.23x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 4.80x to 3.23x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | CN¥2.39 | CN¥11.46 | x |
| 2022-12-31 | CN¥2.79 | CN¥11.46 | x |
| 2023-12-31 | CN¥3.13 | CN¥11.46 | x |
| 2024-12-31 | CN¥3.55 | CN¥11.46 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Yili Chuanning Biotechnology Co. Ltd. A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 17.73%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 24.32%
- • Asset Turnover: 0.55x
- • Equity Multiplier: 1.34x
- Recent ROE (17.73%) is above the historical average (10.05%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 2.33% | 3.45% | 0.34x | 1.98x | CN¥-365.78 Million |
| 2022 | 6.63% | 10.77% | 0.37x | 1.67x | CN¥-208.93 Million |
| 2023 | 13.51% | 19.50% | 0.48x | 1.46x | CN¥244.52 Million |
| 2024 | 17.73% | 24.32% | 0.55x | 1.34x | CN¥610.57 Million |
Industry Comparison
This section compares Yili Chuanning Biotechnology Co. Ltd. A's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $5,249,192,405
- Average return on equity (ROE) among peers: 10.60%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Yili Chuanning Biotechnology Co. Ltd. A (301301) | CN¥7.79 Billion | 2.33% | 0.30x | $731.85 Million |
| Shenzhen CAU Technology Co Ltd (000004) | $85.28 Million | -13.04% | 0.97x | $80.66 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $687.82 Million | 11.47% | 1.00x | $1.02 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $134.48 Million | 10.88% | 3.14x | $288.51 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $915.76 Million | -0.65% | 0.06x | $253.71 Million |
| Chengzhi Shareholding Co Ltd (000990) | $997.75 Million | 5.11% | 1.23x | $934.96 Million |
| Hualan Biological EngineeringInc (002007) | $6.88 Billion | 18.64% | 0.10x | $1.99 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $7.66 Billion | 47.23% | 0.35x | $793.09 Million |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $31.94 Billion | 6.87% | 0.05x | $3.75 Billion |
| Baolingbao Biology Co Ltd (002286) | $2.04 Billion | 5.44% | 0.31x | $403.60 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $1.14 Billion | 14.05% | 0.13x | $344.80 Million |